

Introduction Presentation | May 2026

# Disrupting Biofilms to Save Limbs and Transform Wound Care

⚠️ *"Every 4 minutes, a diabetic patient in America loses a limb."*

**Dr. Robert Huizinga**

Interim Chief Executive Officer

✉️ [rhuizinga@kanebiotech.com](mailto:rhuizinga@kanebiotech.com)

🌐 [www.kanebiotech.com](http://www.kanebiotech.com)

---

## Forward-Looking Statements

This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions.

Introductions should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Introductions are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein.

# A Preventable Healthcare Crisis in the US (\$USD)

The human and economic burden of chronic wounds is escalating



**130,000**

Amputations per year among  
diabetic patients

🕒 One every 4 minutes



**10.5M**

Medicare beneficiaries suffering  
from chronic wounds

Non-healing wound population



**700,000**

Burn-related insurance claims  
annually

Includes 29,000 hospital admissions



**>\$100K USD**

Average cost per burn treatment

Massive economic burden

📈 These aren't just statistics. They represent a systemic failure to treat the root cause of chronic infections.

SOURCE: CMS DATA / CDC



# A Preventable Healthcare Crisis in Canada (\$CAD)

\* Excludes outpatient care, rehabilitation, prosthetics, and long-term support.



**\$47,000**

Average cost per hospitalization for a diabetic amputation



**\$750M**

Annual hospitalization costs for diabetes-related lower limb complications (including amputations, ulcers, gangrene, infections)




**>\$12 Billion**

Estimated annual direct spending on total wound care in Canada  
Massive economic burden



**3-5 Times**

First Nations people in Canada face significantly higher rates of diabetes-related amputations—often 3–5 times higher than others, or up to 18 times higher in specific regions like Manitoba

 These aren't just statistics. They represent our inability to treat the root cause of chronic infections.

- Canadian Institute for Health Information (CIHI), 2024. Equity in diabetes care: A focus on lower limb amputation. <https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation>
- Queen D, Botros M. 2024. The true cost of wounds for Canadians. Wound Care Canada. 22(1): 16-20. DOI: 10.56885/NXMW2913
- Shah BR, Frymire E, Jacklin K, Jones CR, Khan S, Slater M, Walker JD, Green ME. Peripheral arterial disease in Ontario First Nations people with diabetes: a longitudinal population-based cohort study. CMAJ Open. 2019 Dec 10;7(4):E700-E705. doi: 10.9778/cmajo.20190162. PMID: 31822500; PMCID: PMC7015673.

# Biofilms: The 1,000X Problem

Why standard treatments fail to heal chronic wounds

## The Hidden Culprit

**70%** of burn wounds contain biofilm layers



**80%** of chronic wounds have established biofilms

**1,000x** more resistant to antibiotics than regular bacteria

**i** Physical or chemical disruption of biofilm before bacterial killing is needed.

## What Is A Biofilm?

- 🛡️ A protective microscopic matrix created by bacteria to defend themselves
- 🚫 Reduces metabolic activity (making bacteria "invisible" to immune system)
- 🚫 Shields bacteria from antibiotics, disinfectants, and host defenses



## THE TREATMENT GAP

Whether from diabetes, burns, or surgery, effective wound care **MUST** treat both bacteria **AND** biofilms. Current products often don't.

## Why Current Solutions Fail

Existing standards of care leave critical gaps in treatment: **revyve**<sup>®</sup> has the potential to be the standard of care.

 <p><b>Surgical Debridement</b></p>	 <p><b>Current Hydrogels</b></p>	 <p><b>Advanced Dressings</b></p>	 <p><b>Antibiotic Treatments</b></p>
<ul style="list-style-type: none"> <li>✗ Painful and traumatic procedure</li> <li>✗ Expensive, requires clinic visit</li> <li>✗ Biofilms reform within 24 hours</li> </ul> <hr/> <p>✓ Removes necrotic tissue</p>	<ul style="list-style-type: none"> <li>✗ No biofilm disruption capability</li> <li>✗ Limited antimicrobial duration</li> <li>✗ Requires daily dressing changes</li> </ul> <hr/> <p>✓ Maintains moisture balance</p>	<ul style="list-style-type: none"> <li>✗ Extremely high cost (\$1,000+)</li> <li>✗ Limited reimbursement access</li> <li>✗ Do not actively disrupt biofilms</li> </ul> <hr/> <p>✓ Creates supportive environment</p>	<ul style="list-style-type: none"> <li>✗ Poor penetration into biofilms</li> <li>✗ Drives antibiotic resistance</li> <li>✗ Systemic side effects &amp; dosing issues</li> </ul> <hr/> <p>✓ Only treats planktonic bacteria</p>



### The Gap in Standard of Care

No existing solution addresses: Biofilm Disruption + Sustained Antimicrobial + Ease of Use + Reimbursement

# \$423M - \$493M US Market Opportunity

**TOTAL TAM: \$400M - \$500M**

Addressing massive unmet needs across multiple care settings



## \$350M Chronic Wounds

- ✓ Diabetic Foot Ulcers (DFUs)
- ✓ Venous/Arterial Leg Ulcers
- ✓ Pressure Ulcers

### Care Setting Mix:



## \$80-150M Inpatient Burn/Wound

- ✓ 450,000 Burn Patients/Year
- ✓ Large Surface Area Wounds
- ★ **Spray Format Advantage**

Hospital Burn Centers & Trauma

### Market Growth Drivers

**Ageing Population**  
10,000 boomers turn 65 daily

**Diabetes Epidemic**  
37M Americans (11.6% of US population)

**Surgical Volume**  
Rising post-op needs

**Antibiotic Crisis**  
Need for non-antibiotic options

Sources: Grandview Research, metatech insights, gminsights, marketresearch.com

## revyve®: Three Mechanisms in One

The first technology to disrupt biofilms, kill bacteria, and support healing



### Biofilm Disruption

Patented **coactiv+** technology breaks down the biofilm matrix structure, exposing bacteria and reducing elevated protease activity.

✓ Physical & chemical disruption



### Antimicrobial Killing

Sustained killing of bacteria for up to **7 days** without antibiotics. Effective against multi-species and resistant strains.

✓ No antibiotic resistance



### Healing Support

Thermo-reversible gel supports **autolytic debridement** and maintains optimal moist wound environment for healing.

✓ Easy application & removal



THE SOLUTION


### THE REVYVE® ADVANTAGE: COMPLETE CARE

- ✓ Disrupts biofilms + antimicrobial action
- ✓ Fewer dressing changes (7-day duration)
- ✓ Works with existing dressing protocols
- ✓ Non-contact spray option reduces pain

# 7-Day Biofilm Killing Power

Sustained activity against antibiotic-resistant pathogens without regrowth


- >4 Log Reduction (99.99%+ Kill Rate)
- Sustained 7-Day Activity (No Regrowth)
- Effective vs. Antibiotic-Resistant Strains (MRSA)
- Mature 72h Biofilm Model



Drake M., Visvalingam J., Sailer, M., Huizinga RB. (2025) Antimicrobial and Antibiofilm efficacies of a thermo-reversible Antimicrobial Wound Gel. Southern Region Burn Conference, Charleston, USA

# Real World Case Series – Multiple Centers

Consistent outcomes across 9 leading wound care centers in the US and Canada



## Participating Clinical Centers

- ✓ NY: Mount Sinai West
- ✓ NC: UNC (Chapel Hill)
- ✓ NC: Raleigh Foot & Ankle
- ✓ NC: Foot & Ankle Institute
- ✓ MO: St. Louis Foot & Ankle
- ✓ PA: Georgiades Surgical
- ✓ CO: The WISH Clinic
- ✓ GA: Burn & Reconstructive
- ✓ ON: Quinte Health Care

## Case Series Design

- 👥 **Patient Mix:** Diabetic Foot Ulcers, Venous Leg Ulcers, Surgical Wounds
- 📄 **Protocol:** Real-world clinical practice; various dressing types
- 🕒 **Frequency:** Typical dressing changes (2-3x/week to weekly)

## PRELIMINARY FINDINGS

Q4 2025 – Q1 2026

**High rate of conversion from non-healing to healing transition**

- ✓ **Outcomes:** Significant pain reduction & improved wound bed preparation
- ✓ **Feedback:** Positive clinician response on ease of application

📄 **Peer-reviewed publication in preparation**

## From Non-Healing to Healed

Disrupting biofilms changes outcomes for chronic wound patients



### Case Study 1: 52-Year-Old Male with Diabetic Foot Ulcer

History: Multiple unsuccessful treatments prior to revyve®

Quinte Health Care



Day 1

Baseline



Day 97

Near closure



After Study End

FULLY HEALED



### Case Study 2: 62-Year-Old Female with Chronic Venous Leg Ulcer

History: Recurrent since 2013. Comorbidities: Diabetes, Obesity, chronic phlebolympheidema

Pain: 10 → 0 (Week 6)



Week 1

Pain 10/10



Week 8

Pain 0/10



Week 33 (Follow-up)

SUSTAINED HEALING

# Product Portfolio

Two FDA-cleared formats covering the full spectrum of wound care needs



## Antimicrobial Wound Gel

Tube Format (85g/3 oz)

- ✓ **Thermo-reversible:** Liquid at cool temp, gel at body temp
- ✓ **Ease of Use:** Easy to apply, stays in place, rinses off easily
- ✓ **Indications:** DFUs, leg ulcers, pressure ulcers, surgical incisions

- ✓ FDA 510(k) Cleared
- ✓ Health Canada Approved
- ✓ Medicare Reimbursable



### Target Markets

Outpatient Clinics • Podiatry • Long-Term Care • Home Health



## Antimicrobial Wound Spray

Non-Aerosol Spray (5 oz)

- ✓ **Zero-Contact:** Painless application for sensitive wounds
- ✓ **Technology:** Thick gel spray adheres to vertical surfaces
- ✓ **Indications:** Large surface burns, trauma, painful wounds

- ✓ FDA 510(k) Cleared
- ✓ Health Canada Approved
- ✓ Patent Pending Delivery



### Target Markets

Burn Centers • Trauma Centers • Emergency Dept • Inpatient

## Competitive Differentiation

### vs. Standard Hydrogels

- + Adds biofilm disruption + antimicrobial
- + 7-day duration (vs daily)

### vs. Antibiotic Ointments

- + No resistance development
- + Penetrates biofilms effectively

### vs. Advanced Biologics

- + Accessible pricing (vs \$1,000+)
- + No specialized training needed

# Transforming Wound Care

Preventing amputations. Creating shareholder value.

The Problem	The Solution	The Market	The Inflection	The Investment
<p><b>130,000</b></p> <p>AMPUTATIONS / YEAR</p> <ul style="list-style-type: none"> <li>Biofilms block healing</li> <li>1,000X antibiotic resistance</li> <li>Current products fail</li> </ul>	<p><b>revyve®</b></p> <p>DISRUPTS &amp; KILLS</p> <ul style="list-style-type: none"> <li>Breaks biofilm matrix</li> <li>7-Day antimicrobial</li> <li>FDA Cleared &amp; Reimbursed</li> </ul>	<p><b>\$423M+ USD</b></p> <p>US ADDRESSABLE MARKET</p> <ul style="list-style-type: none"> <li>Aging &amp; Diabetes growth</li> <li>Resistance crisis tailwinds</li> <li>Cost-saving solution</li> </ul>	<p><b>NOW</b></p> <p>EXECUTION PHASE</p> <ul style="list-style-type: none"> <li>Technical risk eliminated</li> <li>Commercial launch 2026</li> <li>Distribution imminent</li> </ul>	<p><b>VALUE</b></p> <p>ASYMMETRIC UPSIDE</p> <ul style="list-style-type: none"> <li>De-risked asset</li> <li>Undervalued potential</li> <li>Near-term catalysts</li> </ul>

**Three Paths to Value Creation**

<p><b>1. Organic Growth</b></p> <p>Execute 2026 commercial plan to reach break-even in 2027.</p>	<p><b>2. Strategic Partnership</b></p> <p>Leverage IP for international licensing deals to generate non-dilutive capital.</p>	<p><b>3. Acquisition</b></p> <p>Attractive target for med-tech leaders seeking wound care innovation &amp; antibiotic alternatives.</p>
--	---	---

*"We are building a company, not just running a science project. We will be accountable to these milestones. We will communicate transparently. And we will create value for shareholders who believe in this mission."*

**Dr. Robert Huizinga**  
Interim CEO

# Partner With Us to Transform Wound Care

Join us in preventing amputations and creating shareholder value



**Dr. Robert Huizinga, PhD, RN**

Interim Chief Executive Officer

✉ [rhuizinga@kanebiotech.com](mailto:rhuizinga@kanebiotech.com)

🌐 [www.kanebiotech.com](http://www.kanebiotech.com)



**Ray Dupuis, CPA, MBA**

Chief Financial Officer

✉ [rdupuis@kanebiotech.com](mailto:rdupuis@kanebiotech.com)

📠 [ir@kanebiotech.com](mailto:ir@kanebiotech.com)

TSX VENTURE

**KNE**

~\$0.04 CAD

OTC MARKETS

**KNBIF**

US Symbol



**"We're transforming wound care—be part of this journey."**